The particulars: 98.4% · PeptideMeter · 97.1% · Medutest.
The comparison I want does not seem to exist anywhere in a form I can evaluate.
I have read the arguments for each and they do not engage with each other.
So which one, and on what grounds?
The particulars: 98.4% · PeptideMeter · 97.1% · Medutest.
The comparison I want does not seem to exist anywhere in a form I can evaluate.
I have read the arguments for each and they do not engage with each other.
So which one, and on what grounds?
98.4 and 97.1 are 1.3 percentage points apart, which sounds small until you restate it as impurity. PeptideMeter is leaving 1.6 per cent of the detected area unassigned and Medutest 2.9 per cent — a factor of 1.81 between them. The impurity fraction is the quantity that moves when a method changes, and it is the one worth arguing about; the headline is just its complement. Comparable means same column chemistry, same gradient slope, same detection wavelength, same integration convention. Until you have those four from both laboratories, 98.4 and 97.1 are two measurements of slightly different quantities that happen to share a unit.
Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.
Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
| Δ mass (Da) | Most likely cause | Distinguishing feature |
|---|---|---|
| +1 | Deamidation (Asn or Gln) | New peak, slightly earlier retention |
| −17 | Loss of ammonia | Often with deamidation |
| −18 | Dehydration / succinimide | pH-dependent, reversible |
| +16 | Oxidation (Met, Trp) | Earlier retention, light-related |
| −128 | Missing Gln or Lys | Deletion sequence from synthesis |
| 0 | Isomer: racemisation or scrambling | Same mass, shifted retention |
On the detail: detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.
Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemThe honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.
Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.
The underlying point is that the fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.
Compare purity within a single laboratory on the same method, never across laboratories.
edited 2 Sept 2024 by assay_blank — added the method parameters
Worth being precise here: gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.
Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.
In practice, retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.
I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.
If you are ranking vendors, specify a method and have all samples tested at the same place.
Stated carefully, understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.
Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.
One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
It helps to be literal here: purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.
Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.